Pathophysiological role of leptin in obesity-related hypertension.
To explore the pathophysiological role of leptin in obesity-related hypertension, we examined cardiovascular phenotypes of transgenic skinny mice whose elevated plasma leptin concentrations are comparable to those seen in obese subjects. We also studied genetically obese KKA(y) mice with hyperleptinemia, in which hypothalamic melanocortin system is antagonized by ectopic expression of the agouti protein. Systolic blood pressure (BP) and urinary catecholamine excretion are elevated in transgenic skinny mice relative to nontransgenic littermates. The BP elevation in transgenic skinny mice is abolished by alpha(1)-adrenergic, beta-adrenergic, or ganglionic blockers at doses that do not affect BP in nontransgenic littermates. Central administration of an alpha-melanocyte-stimulating hormone antagonist causes a marked increase in cumulative food intake but no significant changes in BP. The obese KKA(y) mice develop BP elevation with increased urinary catecholamine excretion relative to control KK mice. After a 2-week caloric restriction, BP elevation is reversed in nontransgenic littermates with the A(y) allele, in parallel with a reduction in plasma leptin concentrations, but is sustained in transgenic mice overexpressing leptin with the A(y) allele, which remain hyperleptinemic. This study demonstrates BP elevation in transgenic skinny mice and obese KKA(y) mice that are both hyperleptinemic, thereby suggesting the pathophysiological role of leptin in some forms of obesity-related hypertension.
Aizawa-Abe
M
M
Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto, Japan.
Ogawa
Y
Y
Masuzaki
H
H
Ebihara
K
K
Satoh
N
N
Iwai
H
H
Matsuoka
N
N
Hayashi
T
T
Hosoda
K
K
Inoue
G
G
Yoshimasa
Y
Y
Nakao
K
K
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure; D001835:Body Weight; D004435:Eating; D002149:Energy Intake; D005730:Ganglionic Blockers / Q000494:pharmacology; D006321:Heart / Q000033:anatomy & histology; D006339:Heart Rate; D018738:Hexamethonium / Q000494:pharmacology; D006973:Hypertension / Q000209:etiology*; D007668:Kidney / Q000033:anatomy & histology; D020738:Leptin / Q000097:blood* / Q000235:genetics; D008297:Male; D009074:Melanocyte-Stimulating Hormones / Q000494:pharmacology; D051379:Mice; D008822:Mice, Transgenic; D008954:Models, Biological; D009765:Obesity / Q000150:complications*; D009929:Organ Size; D013564:Sympathetic Nervous System / Q000187:drug effects; D013599:Systole; D014556:Urine / Q000502:physiology; D000521:alpha-MSH / Q000037:antagonists & inhibitors
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D005730:Ganglionic Blockers; D020738:Leptin; C103272:SHU 9119; D018738:Hexamethonium; D000521:alpha-MSH; D009074:Melanocyte-Stimulating Hormones